Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1979 1
1980 1
1981 2
1982 2
1983 2
1984 3
1985 2
1986 4
1987 4
1988 8
1989 2
1990 1
1991 2
1992 5
1993 10
1994 4
1995 5
1996 8
1997 6
1998 2
1999 4
2000 3
2001 6
2002 6
2003 2
2004 4
2005 5
2006 5
2007 6
2008 7
2009 10
2010 5
2011 11
2012 11
2013 10
2014 16
2015 18
2016 22
2017 23
2018 11
2019 12
2020 18
2021 15
2022 14
2023 13
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

300 results

Results by year

Filters applied: . Clear all
Page 1
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Thompson AJ, et al. Among authors: lublin fd. Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21. Lancet Neurol. 2018. PMID: 29275977 Review.
Clinical Course of Multiple Sclerosis.
Klineova S, Lublin FD. Klineova S, et al. Among authors: lublin fd. Cold Spring Harb Perspect Med. 2018 Sep 4;8(9):a028928. doi: 10.1101/cshperspect.a028928. Cold Spring Harb Perspect Med. 2018. PMID: 29358317 Free PMC article. Review.
How patients with multiple sclerosis acquire disability.
Lublin FD, Häring DA, Ganjgahi H, Ocampo A, Hatami F, Čuklina J, Aarden P, Dahlke F, Arnold DL, Wiendl H, Chitnis T, Nichols TE, Kieseier BC, Bermel RA. Lublin FD, et al. Brain. 2022 Sep 14;145(9):3147-3161. doi: 10.1093/brain/awac016. Brain. 2022. PMID: 35104840 Free PMC article.
Defining the clinical course of multiple sclerosis: the 2013 revisions.
Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B Jr, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH. Lublin FD, et al. Neurology. 2014 Jul 15;83(3):278-86. doi: 10.1212/WNL.0000000000000560. Epub 2014 May 28. Neurology. 2014. PMID: 24871874 Free PMC article.
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Hauser SL, et al. Among authors: lublin f. N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002679 Free article. Clinical Trial.
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Montalban X, et al. Among authors: lublin f. N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002688 Free article. Clinical Trial.
Editors' Welcome.
Banwell B, Giovannoni G, Hawkes C, Lublin F. Banwell B, et al. Among authors: lublin f. Mult Scler Relat Disord. 2015 Nov;4(6):A1-2. doi: 10.1016/j.msard.2015.11.001. Mult Scler Relat Disord. 2015. PMID: 26590672 No abstract available.
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.
Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Lublin FD, Drappa J, Barron G, Madani S, Ratchford JN, She D, Cimbora D, Katz E; N-MOmentum study investigators. Cree BAC, et al. Among authors: lublin fd. Lancet. 2019 Oct 12;394(10206):1352-1363. doi: 10.1016/S0140-6736(19)31817-3. Epub 2019 Sep 5. Lancet. 2019. PMID: 31495497 Clinical Trial.
Editors' Welcome.
Waubant E, Giovannoni G, Hawkes C, Lublin F. Waubant E, et al. Among authors: lublin f. Mult Scler Relat Disord. 2017 Nov;18:A1-A2. doi: 10.1016/j.msard.2017.10.016. Mult Scler Relat Disord. 2017. PMID: 29141832 No abstract available.
Editors' Welcome.
Lublin F, Giovannoni G, Hawkes C, Waubant E. Lublin F, et al. Mult Scler Relat Disord. 2017 Oct;17:A1-A2. doi: 10.1016/j.msard.2017.09.025. Mult Scler Relat Disord. 2017. PMID: 29055486 No abstract available.
300 results